ArticleHypertension (Dallas, Tex. : 1979)2026
Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.
Article in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAcute hypertensive crises can induce intravascular hemolysis, but its impact on the renin-angiotensin system remains unclear.
methodsAcute blood pressure elevations were induced in wild-type and PEP (prolyl endopeptidase)-deficient mice via Ang II (angiotensin II) injections. Systolic blood pressure, hemolysis index, and plasma enzymatic activities were evaluated. Native and cryo-hemolyzed plasma samples were incubated ex vivo with Ang II, with or without a PEP inhibitor, and Ang-(1-7; angiotensin-[1-7]) formation was measured over time. Ang II formation from Ang I (angiotensin I) was also assessed ex vivo. Plasma ACE (angiotensin-converting enzyme) protein levels were determined by Western blotting.
resultsAng II-induced blood pressure elevations led to hemolysis and a ~3.5-fold increase in plasma PEP activity, while the activities of other Ang II-degrading enzymes were unchanged. Pretreatment with recombinant ACE2 before Ang II infusion markedly attenuated both the systolic blood pressure and the hemolysis index. Cryo-hemolyzed plasma from mice and humans showed markedly increased ex vivo Ang-(1-7) formation from Ang II compared with native plasma, which was obliterated by PEP inhibition. In addition, ex vivo Ang II formation from Ang I was markedly decreased in cryo-hemolyzed plasma, and this was associated with reduced ACE activity, while ACE protein levels remained unchanged.
conclusionsAcute severe hypertension induced by Ang II infusion causes intravascular hemolysis associated with increased plasma PEP activity and decreased plasma ACE activity that, based on ex vivo findings, enhance Ang II degradation to form Ang-(1-7) and reduce Ang II formation from Ang I, respectively. These previously unrecognized effects of hemolysis on renin-angiotensin system enzymes may be involved in mechanisms that influence acute blood pressure responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.